Loading patent…
AssigneeSequela, Inc.
InventorsRichard T. COUGHLIN, Stephen L. CARRITHERS, Aaron L. CARRITHERS, Brennan M. CARRITHERS
Estimating the term…
The levels of prouroguanylin (proUGN), or fragments thereof, present in blood are normally low in humans and are proposed to be involved in the physiologic regulation of oral and vascular salt levels in the body. When certain kidney related diseases or kidney dysfunctions occur, the level of proUGN or fragments thereof can rise dramatically and significantly. This rise of proUGN in the serum can be used as a marker to diagnose and, in turn, treat kidney disease, or monitor disease progression of kidney dysfunction, or can be used to predict the outcome of a treatment program for kidney disease and/or dysfunction. The level of proUGN or fragments thereof can be measured by a novel immunological assay, and a positive result above a cut-off value is diagnostic for chronic kidney disease (CKD). The calibration of that immunological assay can be done best by using a full-length appropriately folded and secreted recombinant human protein without any N′- or C′-terminal tags made in a human kidney cell line.
A method of diagnosing and treatment thereof for renal dysfunction or disease and/or renal complications of a disease in a subject, the method comprising:
A method for (i) diagnosing or monitoring kidney function in a subject or (ii) diagnosing kidney disease or renal complications prior to the onset of kidney degeneration in a subject or (iii) predicting or monitoring the risk of an adverse event in a subject with kidney disease wherein said adverse event is selected from the group comprising worsening of kidney dysfunction including kidney failure, loss of kidney function, development of related comorbid condition, end-stage kidney disease, or death, or (iv) predicting or monitoring the success of a therapy or intervention in a subject with kidney disease, the method comprising:
A kit comprising:
Dependencies are inferred from the claim text.